515832-52-7

Basic information

• Product Name: 5-BROMO-2-ISOPROPOXY-BENZONITRILE
• Synonyms: 5-BROMO-2-ISOPROPOXY-BENZONITRILE;AKOS B005926;Albb-008948;5-bromo-2-propan-2-yloxybenzonitrile;5-bromo-2-propan-2-yloxy-benzonitrile
• CAS NO: 515832-52-7
• Molecular Formula: C₁₀H₁₀BrNO
• Molecular Weight: 240.1
• Mol File: 515832-52-7.mol

Chemical Properties

• Boiling Point: 308.5 °C at 760 mmHg
• Flash Point: 140.4 °C
• Appearance: powder
• Density: 1.41 g/cm³
• Vapor Pressure: 0.000676mmHg at 25°C
• Refractive Index: 1.559
• CAS DataBase Reference: 5-BROMO-2-ISOPROPOXY-BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-ISOPROPOXY-BENZONITRILE(515832-52-7)
• EPA Substance Registry System: 5-BROMO-2-ISOPROPOXY-BENZONITRILE(515832-52-7)

Safety Data

• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 515832-52-7(Hazardous Substances Data)

Usage

Uses

5-Bromo-2-isopropoxybenzonitrile is used as pharmaceutical intermediate.

InChI:InChI=1/C10H10BrNO/c1-7(2)13-10-4-3-9(11)5-8(10)6-12/h3-5,7H,1-2H3

Upstream product

• 40530-18-5 5-bromo-2-hydroxybenzonitrile 
• 75-26-3 isopropyl bromide 
• 75-30-9 2-iodo-propane 

Downstream Products

• 1377188-30-1 5-{[4-(hydroxymethyl)phenyl]ethynyl}-2-isopropoxybenzonitrile 
• 1377188-31-2 5-{[4-(chloromethyl)phenyl]ethynyl}-2-isopropoxybenzonitrile 
• 1377188-23-2 5-{[4-(1H-imidazol-1-ylmethyl)phenyl]ethynyl}-2-isopropoxybenzonitrile 
• 1344997-61-0 5-{3-[2-ethyl-3-(2-oxoethyl)phenyl]-1,2,4-thiadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile 
• 1344997-60-9 5-(3-{2-ethyl-3-[(E)-2-(methyloxy)ethenyl]phenyl}-1,2,4-thiadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile 
• 1344998-54-4 C₂₉H₃₄N₄O₃S 
• 1344998-01-1 5-{5-[2-ethyl-3-(3-oxopropyl)phenyl]-1,3-thiazol-2-yl}-2-[(1-methylethyl)oxy]benzonitrile 
• 1344998-00-0 ethyl 3-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]propanoate 
• 1344997-99-4 ethyl (2E)-3-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]-2-propenoate 
• 1344997-77-8 methyl 1-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]methyl}-3-azetidinecarboxylate 
• 1344997-76-7 ethyl 1-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-4-piperidinecarboxylate 
• 1344997-74-5 ethyl 1-{[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]methyl}-4-piperidinecarboxylate 
• 1344997-73-4 methyl 1-{2-[3-(2-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,3-thiazol-5-yl)-2-ethylphenyl]ethyl}-3-azetidinecarboxylate 

Relevant articles and documents

S1P1 AGONIST AND APPLICATION THEREOF

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.

Synthesis and bioevaluation of 1-phenylimidazole-4-carboxylic acid derivatives as novel xanthine oxidoreductase inhibitors

As part of a continuing study, we designed and synthesized four series of 1-phenylimidazole-4-carboxylic acid derivatives as xanthine oxidoreductase (XOR) inhibitors, evaluated their in vitro inhibitory potencies against XOR and hypouricemic effects in mi

Phenylimidazole XOR (Xanthine Oxidoreductase) inhibitor and preparation and application thereof

The invention belongs to the technical field of pharmaceutical and chemical industries and discloses a phenylimidazole XOR (Xanthine Oxidoreductase) inhibitor and the preparation and the application of the phenylimidazole XOR inhibitor. The structure of t

Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors

A diverse library of 1-phenyl-pyrazole-4-carboxylic acid derivatives were synthesized and evaluated for their inhibitory potency against xanthine oxidoreductase (XOR) in vitro and vivo, and the structure-activity relationship (SAR) analyses were also pres

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as a sphingosine 1-phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

PYRIMIDINE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS

Disclosed are pyrimidine derivatives for use as sphingosine 1- phosphate 1 (S1P1) receptor agonists, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions or diseases mediated by S1P1 receptors, particularly multiple sclerosis.

COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS

Compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases mediated by S1P1 receptors.

5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS

5-membered heteroaryl derivatives of formula (I) or salts thereof, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.